Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus.

Ma NY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, Zhang YW, Chen HQ, Lai ST, Jiang GL, Zhao KL.

Int J Clin Oncol. 2014 Apr;19(2):297-302. doi: 10.1007/s10147-013-0564-3. Epub 2013 May 21.

PMID:
23690261
2.

A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus.

Zhao KL, Hu XC, Wu XH, Fu XL, Fan M, Jiang GL.

Invest New Drugs. 2012 Aug;30(4):1585-90. doi: 10.1007/s10637-011-9735-0. Epub 2011 Sep 8.

PMID:
21901403
3.

Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.

Lai X, Gu Q, Zheng X, Liu G, Feng W, Lin X, Mao W.

J Cancer Res Ther. 2016 Oct;12(Supplement):89-95. doi: 10.4103/0973-1482.191612.

4.

Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.

Zhai Y, Hui Z, Wang J, Zou S, Liang J, Wang X, Lv J, Chen B, Zhu H, Wang L.

Dis Esophagus. 2013 Jul;26(5):503-9. doi: 10.1111/j.1442-2050.2012.01380.x. Epub 2012 Aug 2.

PMID:
22862289
5.

Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.

Hsu FM, Lee JM, Huang PM, Lin CC, Hsu CH, Tsai YC, Lee YC, Chia-Hsien Cheng J.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e593-9. doi: 10.1016/j.ijrobp.2011.04.032. Epub 2011 Jun 12.

PMID:
21658851
6.

Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.

Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K.

Jpn J Clin Oncol. 2013 Jun;43(6):608-15. doi: 10.1093/jjco/hyt048. Epub 2013 Apr 12.

PMID:
23585687
7.

Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail.

Meng X, Wang J, Sun X, Wang L, Ye M, Feng P, Zhu G, Lu Y, Han C, Zhu S, Liao Z, Yu J.

Radiother Oncol. 2013 Nov;109(2):275-80. doi: 10.1016/j.radonc.2013.09.008. Epub 2013 Oct 12.

PMID:
24128808
8.

[Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma].

Huang XD, Yi JL, Gao L, Xu GZ, Jin J, Yang WZ, Lu TX, Wu SX, Wu RR, Hu WH, Xie WC, Han F, Gao YH, Gao JM, Pan JJ, Chen CB, Lang JY, Li T, Dong Y, Fu YB, Fan L, Li BS, Li J, Wang XH, Chen BX, Gao XS, Zhang P, Wu XW, Hu BQ.

Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):197-201. Chinese.

PMID:
17649636
9.

Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

Tomblyn MB, Goldman BH, Thomas CR Jr, Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD; SWOG GI Committee.

J Thorac Oncol. 2012 May;7(5):906-12. doi: 10.1097/JTO.0b013e31824c7bed.

10.

Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study.

Zhao Q, Hu G, Xiao W, Chen Y, Shen M, Tang Q, Ning X.

Medicine (Baltimore). 2017 Sep;96(35):e7920. doi: 10.1097/MD.0000000000007920.

11.

Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).

Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, Koizumi W; Kitasato Digestive Disease and Oncology Group.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):872-9. doi: 10.1016/j.ijrobp.2014.03.030. Epub 2014 May 24.

PMID:
24867539
12.

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.

Lu M, Wang X, Shen L, Jia J, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Zhou J, Zhang X.

Cancer Sci. 2016 Apr;107(4):486-90. doi: 10.1111/cas.12894. Epub 2016 Mar 28.

13.

Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients.

Jingu K, Matsushita H, Takeda K, Narazaki K, Ariga H, Umezawa R, Sugawara T, Miyata G, Onodera K, Nemoto K, Yamada S.

Dis Esophagus. 2013 Jul;26(5):522-7. doi: 10.1111/j.1442-2050.2012.01396.x. Epub 2012 Aug 23.

PMID:
22925398
14.
15.

Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.

Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD.

J Clin Oncol. 2010 May 1;28(13):2213-9. doi: 10.1200/JCO.2009.24.8773. Epub 2010 Mar 29.

PMID:
20351330
16.

Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.

Chang KJ, Reid T, Senzer N, Swisher S, Pinto H, Hanna N, Chak A, Soetikno R.

Gastrointest Endosc. 2012 Jun;75(6):1139-46.e2. doi: 10.1016/j.gie.2012.01.042. Epub 2012 Apr 18.

17.

High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.

Wang CY, Deng JY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, Zhang YW, Chen HQ, Perez R, Jiang GL, Zhao KL.

Oncotarget. 2015 Jul 30;6(21):18674-82.

18.

Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.

Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Zhang Z, Xia Y, Guo XM, Jiang GL, Zhao KL.

World J Gastroenterol. 2017 Jan 21;23(3):540-546. doi: 10.3748/wjg.v23.i3.540.

19.

Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer.

Zhang J, Peng F, Li N, Liu Y, Xu Y, Zhou L, Wang J, Zhu J, Huang M, Gong Y.

Radiat Oncol. 2012 Jun 19;7:93. doi: 10.1186/1748-717X-7-93.

20.

Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone.

Zhang P, Xi M, Zhao L, Li QQ, He LR, Liu SL, Shen JX, Liu MZ.

Radiat Oncol. 2014 Nov 26;9:256. doi: 10.1186/s13014-014-0256-9.

Supplemental Content

Support Center